NEW HAVEN, Conn., April 16, 2020 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced
that its Board of Directors has decided to hold the company's 2020
Annual Meeting of Shareholders on Thursday,
April 30, 2020 at 10:00 a.m.
Atlantic Time (9:00 a.m. Eastern
Time) in a virtual-only meeting format due to the evolving
nature of the COVID-19 pandemic and taking into account the
guidance and protocols issued by public health and government
authorities.
As described in the proxy materials for the Annual Meeting
previously distributed, you are entitled to participate in the
Annual Meeting if you were a shareholder of record as of the close
of business on March 17, 2020, the
record date, or hold a legal proxy for the meeting provided by your
bank, broker, or nominee. To attend and vote during the
virtual Annual Meeting at www.issuerdirect.com/virtual-event/BHVN,
you must enter the 16-digit control number included on your proxy
card that you previously received. You may vote or ask
questions during the Annual Meeting by following the instructions
available on www.issuerdirect.com/virtual-event/BHVN. Persons
who do not have a control number may attend as guests but will not
have the option to vote shares or submit questions.
While voting during the virtual Annual Meeting will be
permitted, Biohaven encourages shareholders to vote in advance of
the meeting. Instructions for voting follow:
|
Vote BEFORE the
meeting:
|
Vote by one of the
following methods by 11:59 p.m. Eastern Time on April 29,
2020,
1. Go to
www.proxyvote.com,
2. Call
1-800-690-6903, or
3. Mark, sign and
date your proxy card and return it in the postage-paid
envelope we previously provided.
|
|
Vote DURING the
meeting:
|
Go to
www.issuerdirect.com/virtual-event/BHVN.
Shareholders of
record may attend and vote during the virtual meeting by following
the instructions on this website.
|
The proxy card included with the proxy materials previously
distributed will not be updated to reflect the change in location
and may continue to be used to vote your shares in connection with
the Annual Meeting.
For additional information regarding how you may attend or vote
during the virtual Annual Meeting, please refer to Biohaven's
supplemental proxy materials filed today with the Securities and
Exchange Commission.
About Biohaven
Biohaven is a clinical-stage biopharmaceutical company with a
portfolio of innovative, late-stage product candidates targeting
neurological diseases, including rare disorders. Biohaven has
combined internal development and research with intellectual
property licensed from companies and institutions including
Bristol-Myers Squibb Company, AstraZeneca, Yale University, Catalent, Rutgers, and ALS Biopharma LLC. Currently,
Biohaven's lead development programs include multiple compounds
across its CGRP receptor antagonist, glutamate modulation, and
myeloperoxidase inhibitor platforms. Biohaven's common shares are
listed on the New York Stock Exchange and traded under the ticker
symbol BHVN. More information about Biohaven is available at
www.biohavenpharma.com.
For further information, contact Dr. Vlad Coric, the Chief
Executive Officer at Vlad.Coric@biohavenpharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohaven-changing-2020-annual-meeting-of-shareholders-to-virtual-only-meeting-format-due-to-covid-19-301042413.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.